Security key
75629V104
RECURSION PHARMACEUTICALS, INC. - COMMON STOCK (RXRX)
CUSIP: 75629V104
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 310,182,949
- Total 13F value
- $1,569,493,304
- Share change
- +5,455,034
- Put/Call ratio
- 80%
- SEC-reported price per share
- $5.06
- Number of holders
- 329
- Value change
- +$26,510,398
- Number of buys
- 164
- Number of sells
- 147
- Shares outstanding
- 525,850,455
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
329
Top holders
10
RXRX full security history
Ownership snapshot
Full 13F holder table
RECURSION PHARMACEUTICALS, INC. SEC filings
RECURSION PHARMACEUTICALS, INC. company facts
Broader feeds
Ownership snapshot
Top reported holders of RXRX - RECURSION PHARMACEUTICALS, INC. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BAILLIE GIFFORD & CO
Disclosed value leader
ARK Investment Management...
Comparable rows
2/15
Latest evidence
31 Mar 2025
13F
13D/G
3/4/5
Lead comparable stake: 6.5%
13 rows are not safely comparable across share classes.
13D/G row: BAILLIE GIFFORD & CO
Showing 1-6 of 15 holder rows.
Quick read
BAILLIE GIFFORD & CO leads the comparable SEC ownership view at 6.5%.
2 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BAILLIE GIFFORD & CO's linked filing trail.
Comparable ownership
Top 2
BAILLIE GIFFORD & CO
6.5%
RA CAPITAL MANAGEMENT, L.P.
2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BAILLIE GIFFORD & CO |
13F
13D/G
Company
|
6.5%
Reported 13D/G
· 31 Dec 2024
|
$129,039,050
24,393,015 shares
|
— | 31 Mar 2025 |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
|
2%
Reported 13D/G
· 31 Dec 2024
|
$44,187,549
7,725,096 shares
|
$0 | 31 Dec 2024 |
| Lux Ventures IV, L.P. |
3/4/5
Former 10% Owner
|
—
denominator unverified
|
$137,710,376
13,021,519 shares
|
— | 07 Dec 2021 |
| Mubadala Investment Co PJSC |
3/4/5
13F
10%+ Owner · Company
|
—
denominator unverified
|
$137,333,970
12,985,927 shares
|
— | 02 Mar 2023 |
| Zachary Bogue |
3/4/5
Director, 10%+ Owner
|
—
denominator unverified
|
$39,514,048
3,736,341 shares
|
— | 03 Jul 2023 |
| MIC Capital Partners (Public) Parallel Cayman, LP |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$14,688,335
1,388,889 shares
|
— | 01 Nov 2021 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
329
Shares
310,182,949
Rows available
329
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
330
Q2 2025 holders
329
Holder diff
-1
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|